Stock FULC FULCRUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Real-time Estimate Cboe BZX
Other stock markets
 11:22:23 2024-06-05 am EDT 		5-day change 1st Jan Change
8.445 USD +3.75% Intraday chart for Fulcrum Therapeutics, Inc. +7.72% +24.00%
May. 20 Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target MT
May. 14 Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fulcrum Therapeutics : Corporate Presentation May 2024
PU
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
GL
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
GL
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy in The Lancet Neurology
AQ
Fulcrum Therapeutics to Participate in Upcoming May Conferences
GL
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
GL
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
GL
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
AQ
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
GL
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
GL
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
AQ
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
GL
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
AQ
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
GL
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FULC Stock
  4. News Fulcrum Therapeutics, Inc.
  5. Press Releases